# Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

Source: https://onco.cc/trials/nct06553885/  
OnCo record `nct06553885` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of enfortumab vedotin in colorectal cancer, run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting.

## Summary

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC is a phase 2, interventional study registered as NCT06553885 by H. Lee Moffitt Cancer Center and Research Institute, with a registry enrolment figure of 40 participants, started 2025-04-01 and due to reach its primary completion in 2029-09. Interventions recorded: Enfortumab Vedotin. Conditions listed: Metastatic Colorectal Cancer; Hepatocellular Carcinoma. Primary outcome: Overall response rate (ORR). Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06553885
- Phase: 2
- Setting: A Phase II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic Colorectal Cancer or Hepatocellular Carcinoma
- Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06553885: https://clinicaltrials.gov/study/NCT06553885

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- drugs: [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/)
- companies: [Astellas](https://onco.cc/companies/astellas/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06553885.json